iShares Biotechnology ETF
872 hedge funds and large institutions have $5.2B invested in iShares Biotechnology ETF in 2023 Q4 according to their latest regulatory filings, with 123 funds opening new positions, 177 increasing their positions, 377 reducing their positions, and 73 closing their positions.
68% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 73
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
10% more capital invested
Capital invested by funds: $4.71B → $5.2B (+$490M)
5% more funds holding
Funds holding: 832 → 872 (+40)
2.23% more ownership
Funds ownership: 67.03% → 69.26% (+2.2%)
53% less repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 377
75% less call options, than puts
Call options by funds: $353M | Put options by funds: $1.42B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$270M |
| 2 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
+$66.6M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$26.6M |
| 4 |
JP Morgan Chase
New York
|
+$22.5M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$153M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$39.7M |
| 3 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$36.7M |
| 4 |
Goldman Sachs
New York
|
-$29.6M |
| 5 |
Jane Street
New York
|
-$26.4M |
IBB Hedge Fund Activity: Q4 2023 in Review
872 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2023, worth a combined $5.2B — up 10% from $4.71B a quarter earlier.
Buyers outnumbered sellers: 123 funds opened new IBB positions and 73 closed out — a net gain of 50 holders — while 177 added to existing stakes and 377 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $270M. The largest seller was Bank of America, cutting an estimated $153M.
- 872 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2023, up from 832 in Q3 2023.
- Funds reported $5.2B of iShares Biotechnology ETF stock for Q4 2023, up 10% quarter-over-quarter.
- 123 funds opened new iShares Biotechnology ETF positions in Q4 2023 and 73 closed out, a net change of +50 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2023 was Morgan Stanley, an estimated $270M added.
- The largest iShares Biotechnology ETF seller in Q4 2023 was Bank of America, an estimated $153M sold.
Based on aggregated 13F filings for Q4 2023.